Medilink UK Awards:
2020 Winners and Highly Commended


Congratulations to all the winners and those highly commended.



COLLABORATION WITH THE NHS AWARD


WINNER:

SPIRIT HEALTH GROUP


Spirit Health Group (Leicester) has been a partner of the NHS since 2009. Their growing range of products and services empower people to take control of their health, make best use of NHS resources, and use new technology to improve patient outcomes and add value for clinicians.


HIGHLY COMMENDED:
Cievert
(Newcastle) has been providing the NHS with innovative software to better manage cancer patients from diagnosis to recovery for years. They have cut the waiting times of well over 100,000 NHS oncology patients, improved adherence to protocol, and saved clinicians time that is better spent treating patients.

Docobo (Leatherhead, Surrey) has digital health solutions which support care to patients with multiple long-term conditions, including cancer, mental health, musculoskeletal and social isolation.





EXPORT ACHIEVEMENT AWARD


WINNER:

CELLPATH


Cellpath (Powys, Wales) is a family business specialising in the manufacture of worldwide supply of products, consumables and services to the cellular pathology cancer diagnostic market. 

HIGHLY COMMENDED:

TissueMed  (Leeds) - is a company specialising in the development, manufacture and worldwide sales of a surgical sealant technology. 

Bailey Instruments (Manchester) specialises in the manufacture of medical devices (diagnostics for diabetes and neuropathy) and surgical instruments for podiatry, general surgery, and ENT. Bailey Instruments sells to 35 countries internationally.






INNOVATION AWARD


 WINNER:


MAGSTIM


Magstim (Whitland, Wales) is a medical device manufacturer and supplier of Transcranial Magnetic Stimulation (TMS) equipment, coils and complete packages used for both Magstim TMS therapy and neuromodulation research.


RUNNER UP:

SurePulse Medical (Nottingham) - is a vital-signs monitoring company. SurePulse VS is a wireless heart rate (HR) monitor for newborn babies that addresses real clinical needs, supporting patient safety in an entirely new way.

PEDAAT (South Tyneside and Sunderland NHS Foundation Trust, Sunderland) The Paediatric Emergency Department Asthma Assessment Tool (PEDAAT) developed by the South Tyneside and Sunderland NHS Foundation Trust’s Paediatric Emergency Department (PED), identifies asthma patients with inadequate routine care or treatment adherence and provides an intervention. 


Sponsored By:






OUTSTANDING ACHIEVEMENT AWARD


 WINNER:

SYGNATURE DISCOVERY 

Sygnature Discovery (Nottingham) an independent integrated drug discovery and pre-clinical services company. Since 2011, Sygnature have delivered 30 compounds into pre-clinical development, 15 of which have subsequently entered the clinic (Phases I, II and III) in several types of cancer, spinal injury, severe asthma, COPD, dry eye syndrome, Cushing’s syndrome, anti-viral, anti-fungal (invasive aspergillosis) and hereditary angioedema.

HIGHLY COMMENDED:

Kapitex (Wetherby, Yorkshire) - is a specialist in airway intelligence and manufactures and distributes medical devices for tracheostomy, laryngectomy and dysphagia management.

YourGene Health (Manchester) is an international molecular diagnostics group which develops and commercialises genetic products and services; enabling scientific advances to positively impact human health. 


Sponsored By:





START UP AWARD


WINNER:


Neuronostics
 
 


Neuronostics (Exeter) provides diagnostic decision-support tools for neurologists. Its first commercially available clinical indication is a seizure susceptibility technology called BioEP, which enables diagnosis of epilepsy. Highly Commended: Cansense (Swansea) is developing a non-invasive diagnostic for the early detection of cancer using spectroscopy and AI technology on a blood sample. LightOx (Newcastle) is developing light activated drugs for the treatment of oral cancers, with the aim to provide clinicians and patients alternative options to surgery in pre-cancerous and early stage cancer.


HIGHLY COMMENDED:

Cansense (Swansea) is developing a non-invasive diagnostic for the early detection of cancer using spectroscopy and AI technology on a blood sample.

LightOx (Newcastle) is developing light activated drugs for the treatment of oral cancers, with the aim to provide clinicians and patients alternative options to surgery in pre-cancerous and early stage cancer.

Sponsored By: